Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

288

Participants

Timeline

Start Date

November 7, 2019

Primary Completion Date

October 1, 2025

Study Completion Date

October 1, 2025

Conditions
Advanced Solid Tumor Historically Known for High EphA2 ExpressionUrothelial CancerOvarian CancerNon-small Cell Lung CancerHead and Neck CancerTriple Negative Breast CancerGastric/Upper Gastrointestinal Cancer
Interventions
DRUG

BT5528

Participants will receive a 60-minute intravenous infusion of BT5528 once a week (Days 1, 8, 15, and 22) or every other week (Days 1 and 15) on a 4-week cycle at the selected dose.

DRUG

Nivolumab

Participants will receive nivolumab at 480mg intravenous infusion every 4 weeks.

Trial Locations (32)

1070

RECRUITING

Institut Jules Bordet, Brussels

3722

COMPLETED

Severance Hospital, Yonsei University Health System, Seoul

8035

RECRUITING

Hospital Universitario Vall d'Hebron, Barcelona

9000

RECRUITING

Universitair Ziekenhuis Gent (UZ), Ghent

10021

RECRUITING

David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York

19107

RECRUITING

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

21565

COMPLETED

Gachon University Gil Medical Center, Incheon

22031

RECRUITING

Virginia Cancer Specialists, Fairfax

28040

RECRUITING

Hospital Fundación Jimenez Diaz, Madrid

28041

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

28050

RECRUITING

Centro Integral Oncologico Clara Campal, Madrid

34232

RECRUITING

Florida Cancer Specialists, Sarasota

37221

RECRUITING

Sarah Cannon and HCA Research Institute, Nashville

48201

RECRUITING

Barbara Ann Karmanos Cancer Institute, Detroit

53226

WITHDRAWN

Froedtert Hospital and the Medical College of Wisconsin, Milwaukee

73104

RECRUITING

Stephenson Cancer Center (Oklahoma University), Oklahoma City

77030

RECRUITING

MD Anderson Cancer Center, Houston

80218

RECRUITING

Sarah Cannon Research Institute at HealthONE, Denver

89169

COMPLETED

Comprehensive Cancer Centers of Nevada, Las Vegas

92024

RECRUITING

California Cancer Associates for Research and Excellence, Inc., Encinitas

92037

WITHDRAWN

University of California, San Diego (UCSD) - Medical Center, La Jolla

92868

RECRUITING

University of California - Irvine Medical Center, Orange

02215

WITHDRAWN

Dana Farber Cancer Institute, Boston

02905

WITHDRAWN

Women and Infants Hospital, Providence

Unknown

RECRUITING

Cliniques Universitaires Saint-Luc, Brussels

RECRUITING

Antwerp University Hospital (UZA), Edegem

08908

RECRUITING

Institut Catala d'Oncologia - L'Hospitalet, Barcelona

CB2 0QQ

RECRUITING

Cambridge University Hospitals NHS Foundation Trust, Cambridge

LS9 7TF

RECRUITING

The Leeds Teaching Hospitals NHS Trust Of Trust Headquarters, St James's University Hospital, Leeds

W1G 6AD

RECRUITING

Sarah Cannon Research Institute UK, London

M20 4BX

RECRUITING

The Christie NHS Foundation Trust, Manchester

NE7 7DN

RECRUITING

Sir Bobby Robson Cancer Trials Research Centre, The Northern Center for Cancer Care, Freeman Hospital, Newcastle upon Tyne

All Listed Sponsors
lead

BicycleTx Limited

INDUSTRY